SteelPeak Wealth LLC Has $71,000 Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

SteelPeak Wealth LLC trimmed its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 57.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,200 shares of the company’s stock after selling 15,000 shares during the quarter. SteelPeak Wealth LLC’s holdings in ImmunityBio were worth $71,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of ImmunityBio by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 13,539,590 shares of the company’s stock worth $72,708,000 after acquiring an additional 211,065 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in ImmunityBio by 8.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,142,925 shares of the company’s stock valued at $5,737,000 after purchasing an additional 92,991 shares during the last quarter. Sheets Smith Wealth Management raised its position in shares of ImmunityBio by 380.8% in the first quarter. Sheets Smith Wealth Management now owns 945,720 shares of the company’s stock valued at $5,079,000 after purchasing an additional 749,041 shares during the period. Rafferty Asset Management LLC acquired a new stake in shares of ImmunityBio in the fourth quarter worth $3,714,000. Finally, Clearwater Capital Advisors LLC lifted its stake in shares of ImmunityBio by 12.3% in the fourth quarter. Clearwater Capital Advisors LLC now owns 443,299 shares of the company’s stock worth $2,225,000 after buying an additional 48,700 shares during the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Stock Performance

Shares of ImmunityBio stock traded up $0.10 during trading on Thursday, reaching $3.98. The company’s stock had a trading volume of 2,852,589 shares, compared to its average volume of 4,987,589. ImmunityBio, Inc. has a one year low of $1.25 and a one year high of $10.53. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -3.59 and a beta of 1.07. The business’s fifty day moving average price is $5.80 and its 200-day moving average price is $5.77.

Analysts Set New Price Targets

Separately, Piper Sandler raised their target price on shares of ImmunityBio from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Monday, April 29th.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.